jcm-logo

Journal Browser

Journal Browser

Interstitial Lung Diseases: New Treatments and Future Directions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 805

Special Issue Editor


E-Mail Website
Guest Editor
The Third Department of Pneumonology and Oncology, National Tuberculosis and Lung Diseases Research Institute, Plocka St. 26, 01-138 Warsaw, Poland
Interests: interstitial lung disease; ANCA-associated vasculitis; orphan lung disease; interstitial pneumonia; rheumatic lung disease; chronic respiratory disorders

Special Issue Information

Dear Colleagues,

Interstitial lung diseases (ILDs) are a diverse group of disorders that lead to progressive lung fibrosis and significant morbidity. These diseases present a considerable challenge in clinical practice due to their heterogeneity and complex pathophysiology. This Special Issue, titled "Interstitial Lung Diseases: New Treatments and Future Directions", will focus on recent breakthroughs in the treatment of ILDs, highlighting novel therapeutic approaches and emerging treatment strategies aimed at improving patient outcomes.

Key topics of interest will include the following:

  • The latest advancements in pharmacologic treatments, such as antifibrotic agents, immunomodulators, and biologic therapies;
  • The role of precision medicine in ILDs, exploring individualized treatment approaches based on genetic, phenotypic, and environmental factors;
  • Investigations into novel drug mechanisms and combination therapies designed to halt or reverse disease progression;
  • The potential impact of emerging treatments, including regenerative medicine, stem cell therapy, and gene therapies, in the future management of ILDs;
  • Future challenges in the long-term management and development of patient-centered care strategies.

This Special Issue aims to provide an in-depth exploration of the evolving landscape of ILD treatment, offering insights into both established and emerging therapies. We invite contributions that focus on innovative treatment strategies, the scientific basis for these interventions, and their potential to transform the management of ILDs.

Dr. Justyna Fijołek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Interstitial Lung Disease (ILD)
  • pulmonary fibrosis
  • orphan lung disease
  • AAV-ILD
  • occupational ILD
  • rheumatic lung disease
  • treatment strategies
  • emerging therapies
  • precision medicine
  • future directions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 2674 KiB  
Review
Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions
by Justyna Fijolek and Anna Sniady
J. Clin. Med. 2025, 14(13), 4631; https://doi.org/10.3390/jcm14134631 - 30 Jun 2025
Viewed by 491
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) represent a complex interplay between autoimmune and fibrotic processes that poses significant diagnostic and therapeutic challenges. The distinction between isolated ANCA-ILD and AAV-ILD remains a subject of ongoing debate, with some researchers [...] Read more.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) represent a complex interplay between autoimmune and fibrotic processes that poses significant diagnostic and therapeutic challenges. The distinction between isolated ANCA-ILD and AAV-ILD remains a subject of ongoing debate, with some researchers proposing that ANCA-ILD may be an early or restricted form of systemic vasculitis. Immunosuppressive therapy is the cornerstone of treatment for both diseases. However, there is increasing evidence that supports the potential role of antifibrotic agents in the management of progressive fibrosis. Management of these diseases requires a personalized approach that incorporates evaluation of biomarkers, imaging findings, and clinical risk factors to guide treatment decisions. Although current therapeutic strategies primarily target systemic inflammation, addressing the fibrotic components of these diseases is crucial for improving outcomes. Furthermore, emerging therapeutic options, such as B-cell depletion and antifibrotic therapies, offer promising outcomes. However, their roles in the treatment of AAV-ILD require further exploration. In this review, we discuss clinical insights and evolving therapeutic strategies for managing AAV and ANCA-positive ILD. In addition, we highlight the importance of early diagnosis and individualized treatment plans in improving the prognosis and quality of life of affected patients. Full article
(This article belongs to the Special Issue Interstitial Lung Diseases: New Treatments and Future Directions)
Show Figures

Figure 1

Back to TopTop